Secondary immunodeficiency is reported in most patients with hematological malignancies
such as chronic lymphocytic leukemia and multiple myeloma. The aim of our review was to …

Bruton´ s tyrosine kinase (BTK) inhibitor (BTKi) s block the B-cell receptor (BCR) signaling
cascade by binding to the BTK enzyme preventing the proliferation and survival of malignant …

Patients with chronic lymphocytic leukemia (CLL) have an increased risk for severe COVID-
19 disease and mortality. The goal of this study was to determine the efficacy of COVID-19 …

Methods We examined 44 consecutive patients with CLL who received two doses of mRNA
vaccine (BNT162b2 or mRNA-1273) between 1/2/21 and 3/12/21 and were tested for anti …

B-cell chronic lymphocytic leukaemia (CLL) is associated with immunosuppression and
patients are at increased clinical risk following SARS-CoV-2 infection. Covid-19 vaccines …

Importance It has become common practice to offer immunocompromised patients with
hematologic cancers a third COVID-19 vaccination dose, but data substantiating this are …

Vaccinations are effective in preventing infections; however, it is unknown if patients with
chronic lymphocytic leukemia (CLL) who are treatment naïve (TN) or receiving Bruton …

COI notes: LER has served as a consultant for AbbVie, AstraZeneca, Pharmacyclics, Vaniam
group, and Verastem, holds minority ownership interest in Abbott Laboratories, and has …

Immunocompromised patients with hematologic malignancies are more susceptible to
COVID-19 and at higher risk of severe complications and worse outcomes compared with …

Simple Summary The urgency of the COVID-19 pandemic has led to accelerated vaccine
development within less than a year. Emerging data suggest that the ability of patients with …